Sigma Healthcare Ltd (ASX: SIG) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Sigma Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Sigma Healthcare Ltd (ASX: SIG)
Latest News
Healthcare Shares
Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?
Mergers & Acquisitions
Own Sigma shares? Here's the latest on the Chemist Warehouse merger
Share Market News
How ASX shares vs. property performed in November
Share Gainers
The top 3 ASX 200 stocks to buy and hold in November revealed
ETFs
Vanguard Australian Shares Index ETF has lifted 20% in a year. Which stocks have contributed most to its rise?
Share Gainers
These are the 10 best ASX 200 shares of 2024 so far
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
11 ASX All Ords shares rising faster than Nvidia over the past year
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
01 Oct 2024 | $0.0050 | 0.00% | Interim | 17 Oct 2024 |
28 Mar 2024 | $0.0050 | 50.00% | Final | 17 Apr 2024 |
25 Sep 2023 | $0.0050 | 100.00% | Interim | 11 Oct 2023 |
30 Mar 2023 | $0.0050 | 100.00% | Final | 18 Apr 2023 |
29 Sep 2022 | $0.0050 | 100.00% | Interim | 12 Oct 2022 |
04 Apr 2022 | $0.0100 | 100.00% | Final | 22 Apr 2022 |
24 Sep 2021 | $0.0100 | 100.00% | Interim | 08 Oct 2021 |
06 Apr 2021 | $0.0100 | 100.00% | Final | 21 Apr 2021 |
19 Sep 2019 | $0.0100 | 100.00% | Interim | 04 Oct 2019 |
03 Apr 2019 | $0.0200 | 100.00% | Final | 29 Apr 2019 |
12 Oct 2018 | $0.0150 | 100.00% | Interim | 29 Oct 2018 |
05 Apr 2018 | $0.0250 | 100.00% | Final | 20 Apr 2018 |
19 Sep 2017 | $0.0250 | 100.00% | Interim | 05 Oct 2017 |
06 Apr 2017 | $0.0300 | 100.00% | Final | 21 Apr 2017 |
20 Sep 2016 | $0.0250 | 100.00% | Interim | 03 Oct 2016 |
06 Apr 2016 | $0.0300 | 100.00% | Final | 21 Apr 2016 |
03 Apr 2014 | $0.0200 | 100.00% | Final | 30 Apr 2014 |
21 Sep 2012 | $0.0200 | 100.00% | Interim | 26 Oct 2012 |
05 Apr 2011 | $0.1500 | 100.00% | Special Cash | 11 May 2011 |
16 Oct 2009 | $0.0300 | 100.00% | Interim | 13 Nov 2009 |
31 Mar 2009 | $0.0400 | 100.00% | Final | 07 May 2009 |
30 Sep 2008 | $0.0300 | 100.00% | Interim | 29 Oct 2008 |
29 Aug 2005 | $0.0200 | 100.00% | Interim | 15 Sep 2005 |
02 Mar 2004 | $0.2000 | 100.00% | Final | 23 Mar 2004 |
SIG ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Sigma Healthcare Ltd
Sigma Healthcare is an Australian pharmaceutical distributor, wholesaler and pharmacy franchisor. The revenue growth prospects and returns of pharmaceutical distribution are subdued due to ongoing Pharmaceutical Benefits Scheme, or PBS, price reform, and regulated wholesale gross margins being capped at 7% for community pharmacy. As a result, Sigma and its competitors are seeking to expand into unregulated revenue streams. In addition, pharmacy ownership is restricted to pharmacists, thereby excluding direct corporate ownership and requiring exposure via a franchise business model.
SIG Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Dec 2024 | $2.65 | $0.01 | 0.38% | 2,438,039 | $2.64 | $2.70 | $2.63 |
24 Dec 2024 | $2.64 | $0.02 | 0.76% | 1,400,985 | $2.64 | $2.69 | $2.59 |
23 Dec 2024 | $2.62 | $0.02 | 0.77% | 2,786,560 | $2.60 | $2.65 | $2.59 |
20 Dec 2024 | $2.60 | $-0.03 | -1.14% | 9,656,715 | $2.62 | $2.67 | $2.60 |
19 Dec 2024 | $2.63 | $-0.08 | -2.95% | 6,293,378 | $2.64 | $2.73 | $2.61 |
18 Dec 2024 | $2.71 | $-0.01 | -0.37% | 6,266,111 | $2.70 | $2.78 | $2.68 |
17 Dec 2024 | $2.72 | $0.05 | 1.87% | 9,565,765 | $2.73 | $2.77 | $2.64 |
16 Dec 2024 | $2.67 | $-0.12 | -4.30% | 14,795,564 | $2.74 | $2.75 | $2.57 |
13 Dec 2024 | $2.79 | $0.05 | 1.82% | 4,596,290 | $2.75 | $2.82 | $2.72 |
12 Dec 2024 | $2.74 | $-0.08 | -2.84% | 7,371,405 | $2.83 | $2.84 | $2.66 |
11 Dec 2024 | $2.82 | $0.00 | 0.00% | 6,060,467 | $2.80 | $2.87 | $2.80 |
10 Dec 2024 | $2.82 | $-0.06 | -2.08% | 4,861,474 | $2.86 | $2.88 | $2.79 |
09 Dec 2024 | $2.88 | $0.00 | 0.00% | 5,288,299 | $2.90 | $2.93 | $2.82 |
06 Dec 2024 | $2.88 | $0.01 | 0.35% | 5,722,506 | $2.87 | $2.90 | $2.86 |
05 Dec 2024 | $2.87 | $-0.03 | -1.03% | 7,755,739 | $2.89 | $2.93 | $2.84 |
04 Dec 2024 | $2.90 | $-0.01 | -0.34% | 5,592,131 | $2.91 | $2.92 | $2.85 |
03 Dec 2024 | $2.91 | $0.05 | 1.75% | 8,515,254 | $2.87 | $2.96 | $2.85 |
02 Dec 2024 | $2.86 | $-0.03 | -1.04% | 9,449,624 | $2.95 | $3.01 | $2.82 |
29 Nov 2024 | $2.89 | $0.11 | 3.96% | 7,733,551 | $2.82 | $2.92 | $2.76 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
10 Jul 2024 | Christopher Roberts | Buy | 3,661 | $4,680 |
Directors' share plan.
|
10 Jul 2024 | Neville Mitchell | Buy | 4,340 | $5,548 |
Directors' share plan.
|
10 Jul 2024 | Kathryn (Kate) Spargo | Buy | 4,747 | $6,067 |
Directors' share plan.
|
10 Jul 2024 | Michael Sammells | Buy | 7,866 | $10,054 |
Directors' share plan.
|
10 Jul 2024 | Annette Carey | Buy | 3,662 | $4,681 |
Directors' share plan.
|
08 Apr 2024 | Annette Carey | Buy | 3,656 | $4,459 |
Directors' share plan.
|
08 Apr 2024 | Michael Sammells | Buy | 7,855 | $9,582 |
Directors' share plan.
|
08 Apr 2024 | Kathryn (Kate) Spargo | Buy | 4,740 | $5,782 |
Directors' share plan.
|
08 Apr 2024 | Neville Mitchell | Buy | 4,334 | $5,286 |
Directors' share plan.
|
08 Apr 2024 | Christopher Roberts | Buy | 3,657 | $4,461 |
Directors' share plan.
|
29 Jan 2024 | Neville Mitchell | Issued | 6,474 | $4,531 |
Rights issue.
|
29 Jan 2024 | Michael Sammells | Issued | 81,444 | $57,010 |
Rights issue.
|
29 Jan 2024 | Kathryn (Kate) Spargo | Issued | 129,730 | $90,811 |
Rights issue.
|
29 Jan 2024 | Kathryn (Kate) Spargo | Issued | 111,548 | $78,083 |
Rights issue.
|
29 Jan 2024 | Annette Carey | Issued | 3,708 | $2,595 |
Rights issue.
|
10 Jan 2024 | Michael Sammells | Buy | 10,612 | $10,079 |
Directors' share plan.
|
10 Jan 2024 | Annette Carey | Buy | 4,697 | $4,461 |
Directors' share plan.
|
10 Jan 2024 | Kathryn (Kate) Spargo | Buy | 5,442 | $5,169 |
Directors' share plan.
|
10 Jan 2024 | Christopher Roberts | Buy | 4,696 | $4,460 |
Directors' share plan.
|
10 Jan 2024 | Neville Mitchell | Buy | 5,566 | $5,286 |
Directors' share plan.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Christopher Graham Roberts | Non-Executive Director | Oct 2023 |
Dr Roberts has more than 40 years' experience in the medical device industry, Executive Vice President of ResMed Inc (NYSE:RMD) from 1992 to 2003 and as a Director until November 2017. He Held Directorship in Nutromics Pty Ltd, Atmo Biosciences Limited and the Cochlear Foundation Board. He is also a Governor of the Centenary Institute Cancer Medicine and Cell Biology.
|
Mr Neville Mitchell | Non-Executive Director | Feb 2023 |
Mr Mitchell has financial experience coupled with experience as an active Non-Executive Director. Mr Mitchell is a current Director and Chair of the Audit Committee of Sonic Healthcare. Mr Mitchell is also a Non-Executive Director and Chair of the Audit and Risk Committee of Fisher and Paykel Healthcare. Previously, Mr Mitchell has held other Director roles including South Eastern Sydney Local Health District, The Board of Taxation, Sirtex Medical and Osprey Medical Inc. Mr Mitchell is a qualified Chartered Accountant with international healthcare and finance experience. Prior to becoming a Non-Executive Director, Mr Mitchell had a career spanning 27 years with Cochlear Limited, 22 of those years as Chief Financial Officer and Company Secretary.
|
Ms Kathryn (Kate) Dianne Spargo | Non-Executive Director | Dec 2015 |
Ms Spargo has gained business experience as an advisor, having worked in private practice and government, and as a director of listed and unlisted companies. Ms Spargo is currently a Non-Executive Director at the following listed entities is Sonic Healthcare Limited, Adairs Limited and Bapcor Ltd. In addition Ms Spargo is also currently a Non-Executive Director at CIMIC Ltd (now unlisted). Over the last three years, Ms Spargo was a Non-Executive Director at Xenith IP Ltd. In September 2021, Ms Spargo retired from her position as Chairman of CoInvest and at the same time joined the board of the unlisted company Jellis Craig. Ms Spargo is also Director at the Geelong Football Club and Future Fuels Cooperative Research Centre.
|
Mr Michael Sammells | Non-Executive DirectorInterim Chairman | Feb 2020 |
Mr Sammells has 35 years of broad experience in finance, corporate services and has held operational roles with expertise in finance, accounting, treasury, investor relations, capital developments, mergers and acquisitions and IPOs. Mr Sammells is a current Director of GMHBA Limited and is a former Chief Financial Officer of Healthscope Limited and Medibank Private.
|
Mr Vikesh Ramsunder | Chief Executive OfficerManaging Director | Feb 2022 |
Mr Ramsunder has culmination of a 28 year career with the Clicks Group which included 18 years as part of the executive team. Before becoming Clicks CEO Vikesh held a number of roles within the Group, including Chief Operating Officer from 2015 and Managing Director of the pharmaceutical wholesaler business, United Pharmaceutical Distributors.
|
Ms Annette May Carey | Non-Executive Director | Apr 2023 |
Ms Carey is a current Director of National Intermodal Corporation, a Non-Executive Director of Flinders Port Holdings Pty Ltd, a Non-Executive Director of Kinetic, and an Advisory Board Member of Orizontas. Prior to that, Ms Carey has been a Director of Linfox Armaguard Pty Ltd and Sai Cheng Logistics Inc and was Chair of Australia Post Global. Ms Carey brings a balance of technical expertise as well as legal, strategic, and commercial intellect from over 20 years' experience in supply chain, logistics and cross border ecommerce. Ms Carey has previously held various senior roles within the Linfox Logistics group progressing from General Counsel and Company Secretary to Chief Executive Officer. Ms Carey also held the position of Executive General Manager International with Australia Post. Ms Carey is a member of Chief Executive Women.
|
Ms Kara McGowan | General CounselCompany Secretary | Oct 2021 |
-
|
Kara McGowan | General CounselCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Hmc Capital Partners Holdings Pty Ltd | 311,242,135 | 19.07% |
Hsbc Custody Nominees (Australia) Limited | 295,751,528 | 18.12% |
Citicorp Nominees Pty Limited | 248,058,343 | 15.20% |
J P Morgan Nominees Australia Pty Limited | 164,445,049 | 10.08% |
National Nominees Limited | 64,967,710 | 3.98% |
Sigma Employee Share Admin P/L | 37,184,497 | 2.28% |
Pacific Custodians Pty Limited | 32,103,793 | 1.97% |
Ubs Nominees Pty Ltd | 27,854,014 | 1.71% |
Bnp Paribas Nominees Pty Ltd | 12,983,279 | 0.80% |
Hsbc Custody Nominees (Australia) Limited II | 11,673,531 | 0.72% |
Bnp Paribas Noms Pty Ltd | 11,172,115 | 0.68% |
Invia Custodian Pty Limited | 7,596,481 | 0.47% |
Hsbc Custody Nominees (Australia) Limited A/C 2 | 7,365,783 | 0.45% |
Warbont Nominees Pty Ltd | 5,805,877 | 0.36% |
Lygon Finance Pty Ltd | 4,906,459 | 0.30% |
Citicorp Nominees Pty Limited II | 4,794,059 | 0.29% |
Merrill Lynch (Australia) Nominees Pty Limited | 4,281,681 | 0.26% |
Bnpp Noms Pty Ltd Hub24 Custodial Serv Ltd | 4,049,515 | 0.25% |
Bnp Paribas Nominees Pty Ltd Barclays | 3,406,856 | 0.21% |
Netwealth Investments Limited | 3,315,488 | 0.20% |